NTRA News and Press, Natera Inc. From 09/11/20

Natera  (NASDAQ: NTRA ) has priced its public offering of ~4.2M common shares at $60.00/share. More news on: Natera, Inc., Healthcare stocks news, Read more ...

SAN CARLOS, Calif. , Sept. 10, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference taking place virtually on Mon...

Natera ( NTRA -0.2% )   announced that the CMS Molecular Diagnostics Program has finalized a local coverage determination to provide medicare benefits for serial use of the Signatera molecular residual disease (MRD) test in patients with stage II or III colorectal cancer. More new...

SAN CARLOS, Calif. , Sept. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program (MOLDX) has finalized a local coverage determination (LCD) to provide Medicare benefits for se...

SAN CARLOS, Calif. , Sept. 2, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and leader in cell-free DNA testing, today announced the unblinding of the SMART clinical trial data, and the validation of an artificial intelligence-based (AI) platform as part of its Pano...

SAN CARLOS, Calif. , Sept. 1, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a prospective, randomized controlled trial showing clinical utility of the Prospera test. The study concluded t...

SAN CARLOS, Calif. , Aug. 27, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a collaborative agreement with Mass General Cancer Center (MGCC) of Massachusetts General Hospital, related to an investigator-ini...

Natera ( NTRA +1.1% ) receives CE mark for its Signatera test , a tumor-informed ctDNA assay intended to detect and quantify how much cancer is left in the body, to detect recurrence earlier and to help optimize treatment decisions. More news on: Natera, Inc., Healthcare stocks news, ...

SAN CARLOS, Calif. , Aug. 26, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has received the CE mark for the Signatera test, a personalized, tumor-informed ctDNA assay optimized for molecular residu...

SAN CARLOS, Calif. , Aug. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) , a leader in non-invasive prenatal testing, announced a joint guideline released yesterday by the American College of Obstetrics and Gynecology (ACOG) and Society of Maternal Fetal Medicine (SMFM), regarding ...